-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Chengdu Better Pharmaceuticals has entered the administrative approval stage for the listing of two category 4 generic drugs, namely ticagrelor tablets and febuxostat tablets.
The sales scale of these two products in the terminals of public medical institutions in China in 2020 will be equal.
More than 1.
5 billion yuan
.
According to data from Meinenet, since the beginning of this year, Better Pharmaceuticals has already approved 11 generic drugs with new classifications for production
.
The sales scale of these two products in the terminals of public medical institutions in China in 2020 will be equal.
More than 1.
5 billion yuan
.
According to data from Meinenet, since the beginning of this year, Better Pharmaceuticals has already approved 11 generic drugs with new classifications for production
.
Source: official website of the State Food and Drug Administration
Ticagrelor is a new type of oral antiplatelet drug developed by AstraZeneca.
It is clinically used for acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction or ST-segment Elevation of myocardial infarction) patients, reduce the incidence of thrombotic cardiovascular events
.
The global sales of the original research products in 2020 will be US$1.
593 billion
.
It is clinically used for acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction or ST-segment Elevation of myocardial infarction) patients, reduce the incidence of thrombotic cardiovascular events
.
The global sales of the original research products in 2020 will be US$1.
593 billion
.
AstraZeneca’s ticagrelor tablets were approved to enter the domestic market in November 2012.
Shenzhen Xinlitai won the first imitation in August 2018.
At present, 21 domestic companies have approved the production of ticagrelor tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020 , a year-on-year increase of 11.
22%
.
Shenzhen Xinlitai won the first imitation in August 2018.
At present, 21 domestic companies have approved the production of ticagrelor tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020 , a year-on-year increase of 11.
22%
.
From the perspective of the competitive landscape of manufacturers, the original research manufacturer AstraZeneca still dominates the market, but its market share is declining year by year due to the impact of generic drugs.
The market shares of Xinlitai, CSPC, Huilun Jiangsu Pharmaceutical, Yangzijiang and other companies have steadily increased
.
The market shares of Xinlitai, CSPC, Huilun Jiangsu Pharmaceutical, Yangzijiang and other companies have steadily increased
.
At present, more than 30 domestic companies have submitted applications for the listing of ticagrelor tablets under the new registration classification, of which 20 have been approved for production and deemed to have been reviewed.
In addition, there are Chengdu Better Pharmaceuticals, Chengdu Baiyu Pharmaceuticals, and China Resources Double Crane The products of 10 companies including the pharmaceutical industry are under review.
Among them, the products of Chengdu Better Pharmaceutical have entered the administrative examination and approval stage, sprinting into the 21st domestic market
.
In addition, there are Chengdu Better Pharmaceuticals, Chengdu Baiyu Pharmaceuticals, and China Resources Double Crane The products of 10 companies including the pharmaceutical industry are under review.
Among them, the products of Chengdu Better Pharmaceutical have entered the administrative examination and approval stage, sprinting into the 21st domestic market
.
Source: official website of the State Food and Drug Administration
Febuxostat is a xanthine oxidase (XO) inhibitor developed by Japan's Teijin.
It achieves anti-gout effect by reducing serum uric acid.
It is clinically suitable for long-term treatment of hyperuricemia with gout symptoms
.
It achieves anti-gout effect by reducing serum uric acid.
It is clinically suitable for long-term treatment of hyperuricemia with gout symptoms
.
The original research product was approved to enter the domestic market in September 2018.
At present, 10 domestic companies have approved the production of febuxostat tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020, a year-on-year increase of 7.
8%
.
At present, 10 domestic companies have approved the production of febuxostat tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020, a year-on-year increase of 7.
8%
.
At present, 16 companies have submitted applications for the listing of febuxostat tablets under the new registration classification, of which 7 have been approved for production and deemed to have been reviewed.
In addition, there are products from 8 companies including Chengdu Better Pharmaceuticals and Qingdao Baiyang.
Under review, Chengdu Better Pharmaceutical's products have entered the stage of administrative examination and approval, sprinting to the 10th domestically produced company
.
In addition, there are products from 8 companies including Chengdu Better Pharmaceuticals and Qingdao Baiyang.
Under review, Chengdu Better Pharmaceutical's products have entered the stage of administrative examination and approval, sprinting to the 10th domestically produced company
.
Since 2021, Better Pharmaceuticals (including subsidiaries) has been approved for products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Mi Nei.
com, from 2021 to the present, 11 products of Better Pharmaceuticals (including subsidiaries) have been approved for listing, all of which are reported for production under the new registration classification.
After approved for production, they are deemed to have been reviewed.
Among them, emtricitabine propofol Tenofovir tablets were the first imitation
.
com, from 2021 to the present, 11 products of Better Pharmaceuticals (including subsidiaries) have been approved for listing, all of which are reported for production under the new registration classification.
After approved for production, they are deemed to have been reviewed.
Among them, emtricitabine propofol Tenofovir tablets were the first imitation
.
Source: Meinenet database, official website of the State Drug Administration, etc.
Note: The statistics are as of December 2, if there are any omissions, please correct me!
Recently, Chengdu Better Pharmaceuticals has entered the administrative approval stage for the listing of two category 4 generic drugs, namely ticagrelor tablets and febuxostat tablets.
The sales scale of these two products in the terminals of public medical institutions in China in 2020 will be equal.
More than 1.
5 billion yuan
.
According to data from Meinenet, since the beginning of this year, Better Pharmaceuticals has already approved 11 generic drugs with new classifications for production
.
The sales scale of these two products in the terminals of public medical institutions in China in 2020 will be equal.
More than 1.
5 billion yuan
.
According to data from Meinenet, since the beginning of this year, Better Pharmaceuticals has already approved 11 generic drugs with new classifications for production
.
Source: official website of the State Food and Drug Administration
Ticagrelor is a new type of oral antiplatelet drug developed by AstraZeneca.
It is clinically used for acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction or ST-segment Elevation of myocardial infarction) patients, reduce the incidence of thrombotic cardiovascular events
.
The global sales of the original research products in 2020 will be US$1.
593 billion
.
It is clinically used for acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction or ST-segment Elevation of myocardial infarction) patients, reduce the incidence of thrombotic cardiovascular events
.
The global sales of the original research products in 2020 will be US$1.
593 billion
.
AstraZeneca’s ticagrelor tablets were approved to enter the domestic market in November 2012.
Shenzhen Xinlitai won the first imitation in August 2018.
At present, 21 domestic companies have approved the production of ticagrelor tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020 , a year-on-year increase of 11.
22%
.
Shenzhen Xinlitai won the first imitation in August 2018.
At present, 21 domestic companies have approved the production of ticagrelor tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020 , a year-on-year increase of 11.
22%
.
From the perspective of the competitive landscape of manufacturers, the original research manufacturer AstraZeneca still dominates the market, but its market share is declining year by year due to the impact of generic drugs.
The market shares of Xinlitai, CSPC, Huilun Jiangsu Pharmaceutical, Yangzijiang and other companies have steadily increased
.
The market shares of Xinlitai, CSPC, Huilun Jiangsu Pharmaceutical, Yangzijiang and other companies have steadily increased
.
At present, more than 30 domestic companies have submitted applications for the listing of ticagrelor tablets under the new registration classification, of which 20 have been approved for production and deemed to have been reviewed.
In addition, there are Chengdu Better Pharmaceuticals, Chengdu Baiyu Pharmaceuticals, and China Resources Double Crane The products of 10 companies including the pharmaceutical industry are under review.
Among them, the products of Chengdu Better Pharmaceutical have entered the administrative examination and approval stage, sprinting into the 21st domestic market
.
In addition, there are Chengdu Better Pharmaceuticals, Chengdu Baiyu Pharmaceuticals, and China Resources Double Crane The products of 10 companies including the pharmaceutical industry are under review.
Among them, the products of Chengdu Better Pharmaceutical have entered the administrative examination and approval stage, sprinting into the 21st domestic market
.
Source: official website of the State Food and Drug Administration
Febuxostat is a xanthine oxidase (XO) inhibitor developed by Japan's Teijin.
It achieves anti-gout effect by reducing serum uric acid.
It is clinically suitable for long-term treatment of hyperuricemia with gout symptoms
.
It achieves anti-gout effect by reducing serum uric acid.
It is clinically suitable for long-term treatment of hyperuricemia with gout symptoms
.
The original research product was approved to enter the domestic market in September 2018.
At present, 10 domestic companies have approved the production of febuxostat tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020, a year-on-year increase of 7.
8%
.
At present, 10 domestic companies have approved the production of febuxostat tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020, a year-on-year increase of 7.
8%
.
At present, 16 companies have submitted applications for the listing of febuxostat tablets under the new registration classification, of which 7 have been approved for production and deemed to have been reviewed.
In addition, there are products from 8 companies including Chengdu Better Pharmaceuticals and Qingdao Baiyang.
Under review, Chengdu Better Pharmaceutical's products have entered the stage of administrative examination and approval, sprinting to the 10th domestically produced company
.
In addition, there are products from 8 companies including Chengdu Better Pharmaceuticals and Qingdao Baiyang.
Under review, Chengdu Better Pharmaceutical's products have entered the stage of administrative examination and approval, sprinting to the 10th domestically produced company
.
Since 2021, Better Pharmaceuticals (including subsidiaries) has been approved for products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Mi Nei.
com, from 2021 to the present, 11 products of Better Pharmaceuticals (including subsidiaries) have been approved for listing, all of which are reported for production under the new registration classification.
After approved for production, they are deemed to have been reviewed.
Among them, emtricitabine propofol Tenofovir tablets were the first imitation
.
com, from 2021 to the present, 11 products of Better Pharmaceuticals (including subsidiaries) have been approved for listing, all of which are reported for production under the new registration classification.
After approved for production, they are deemed to have been reviewed.
Among them, emtricitabine propofol Tenofovir tablets were the first imitation
.
Source: Meinenet database, official website of the State Drug Administration, etc.
Note: The statistics are as of December 2, if there are any omissions, please correct me!
Recently, Chengdu Better Pharmaceuticals has entered the administrative approval stage for the listing of two category 4 generic drugs, namely ticagrelor tablets and febuxostat tablets.
The sales scale of these two products in the terminals of public medical institutions in China in 2020 will be equal.
More than 1.
5 billion yuan
.
According to data from Meinenet, since the beginning of this year, Better Pharmaceuticals has already approved 11 generic drugs with new classifications for production
.
The sales scale of these two products in the terminals of public medical institutions in China in 2020 will be equal.
More than 1.
5 billion yuan
.
According to data from Meinenet, since the beginning of this year, Better Pharmaceuticals has already approved 11 generic drugs with new classifications for production
.
Source: official website of the State Food and Drug Administration
Ticagrelor is a new type of oral antiplatelet drug developed by AstraZeneca.
It is clinically used for acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction or ST-segment Elevation of myocardial infarction) patients, reduce the incidence of thrombotic cardiovascular events
.
The global sales of the original research products in 2020 will be US$1.
593 billion
.
It is clinically used for acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction or ST-segment Elevation of myocardial infarction) patients, reduce the incidence of thrombotic cardiovascular events
.
The global sales of the original research products in 2020 will be US$1.
593 billion
.
AstraZeneca’s ticagrelor tablets were approved to enter the domestic market in November 2012.
Shenzhen Xinlitai won the first imitation in August 2018.
At present, 21 domestic companies have approved the production of ticagrelor tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020 , a year-on-year increase of 11.
22%
.
Enterprise Enterprise Enterprise Hospital Hospital HospitalShenzhen Xinlitai won the first imitation in August 2018.
At present, 21 domestic companies have approved the production of ticagrelor tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020 , a year-on-year increase of 11.
22%
.
From the perspective of the competitive landscape of manufacturers, the original research manufacturer AstraZeneca still dominates the market, but its market share is declining year by year due to the impact of generic drugs.
The market shares of Xinlitai, CSPC, Huilun Jiangsu Pharmaceutical, Yangzijiang and other companies have steadily increased
.
The market shares of Xinlitai, CSPC, Huilun Jiangsu Pharmaceutical, Yangzijiang and other companies have steadily increased
.
At present, more than 30 domestic companies have submitted applications for the listing of ticagrelor tablets under the new registration classification, of which 20 have been approved for production and deemed to have been reviewed.
In addition, there are Chengdu Better Pharmaceuticals, Chengdu Baiyu Pharmaceuticals, and China Resources Double Crane The products of 10 companies including the pharmaceutical industry are under review.
Among them, the products of Chengdu Better Pharmaceutical have entered the administrative examination and approval stage, sprinting into the 21st domestic market
.
In addition, there are Chengdu Better Pharmaceuticals, Chengdu Baiyu Pharmaceuticals, and China Resources Double Crane The products of 10 companies including the pharmaceutical industry are under review.
Among them, the products of Chengdu Better Pharmaceutical have entered the administrative examination and approval stage, sprinting into the 21st domestic market
.
Source: official website of the State Food and Drug Administration
Febuxostat is a xanthine oxidase (XO) inhibitor developed by Japan's Teijin.
It achieves anti-gout effect by reducing serum uric acid.
It is clinically suitable for long-term treatment of hyperuricemia with gout symptoms
.
It achieves anti-gout effect by reducing serum uric acid.
It is clinically suitable for long-term treatment of hyperuricemia with gout symptoms
.
The original research product was approved to enter the domestic market in September 2018.
At present, 10 domestic companies have approved the production of febuxostat tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020, a year-on-year increase of 7.
8%
.
At present, 10 domestic companies have approved the production of febuxostat tablets
.
According to data from Mi Nei.
com, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will exceed 1.
5 billion yuan in 2020, a year-on-year increase of 7.
8%
.
At present, 16 companies have submitted applications for the listing of febuxostat tablets under the new registration classification, of which 7 have been approved for production and deemed to have been reviewed.
In addition, there are products from 8 companies including Chengdu Better Pharmaceuticals and Qingdao Baiyang.
Under review, Chengdu Better Pharmaceutical's products have entered the stage of administrative examination and approval, sprinting to the 10th domestically produced company
.
In addition, there are products from 8 companies including Chengdu Better Pharmaceuticals and Qingdao Baiyang.
Under review, Chengdu Better Pharmaceutical's products have entered the stage of administrative examination and approval, sprinting to the 10th domestically produced company
.
Since 2021, Better Pharmaceuticals (including subsidiaries) has been approved for products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
According to data from Mi Nei.
com, from 2021 to the present, 11 products of Better Pharmaceuticals (including subsidiaries) have been approved for listing, all of which are reported for production under the new registration classification.
After approved for production, they are deemed to have been reviewed.
Among them, emtricitabine propofol Tenofovir tablets were the first imitation
.
com, from 2021 to the present, 11 products of Better Pharmaceuticals (including subsidiaries) have been approved for listing, all of which are reported for production under the new registration classification.
After approved for production, they are deemed to have been reviewed.
Among them, emtricitabine propofol Tenofovir tablets were the first imitation
.
Source: Meinenet database, official website of the State Drug Administration, etc.
Source: Meinenet database, official website of the State Drug Administration, etc. Note: The statistics are as of December 2, if there are any omissions, please correct me!
